Clinical Trial Update: Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of IMM 101 with standard of care in metastatic/unresectable cancer has been terminated. Results from the study have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• IMM 101

Snippet

Sponsor: Immodulon Therapeutics Ltd | Conditions: Metastatic Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-11-25